Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0002005369-26-000060·Invus Global Management, LLC
Schedule 13G ownership disclosure
SILENCE THERAPEUTICS PLC
Ordinary share, nominal value 0.05 GBP per share · CUSIP: 82686Q101
Event date: 2026-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Invus Public Equities, L.P.
Shares: 7,591,233.00 · Class: 4.1%
- Invus Public Equities Advisors, LLC
Shares: 7,591,233.00 · Class: 4.1%
- Invus Global Management, LLC
Shares: 7,591,233.00 · Class: 4.1%
- Siren, L.L.C.
Shares: 7,591,233.00 · Class: 4.1%
- Avicenna Life Sci Master Fund LP
Shares: 1,072,368.00 · Class: 0.6%
- Avicenna Life Sci Master GP LLC
Shares: 1,072,368.00 · Class: 0.6%
- Ulys, L.L.C.
Shares: 1,072,368.00 · Class: 0.6%
- Raymond Debbane
Shares: 8,663,601.00 · Class: 4.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0002005369-26-000060
- Form type
- SCHEDULE 13G/A
- Filer
- Invus Global Management, LLC
- CIK
- CIK 2005369
- Filed
- Nov 12, 2026
- Reporting period
- Sep 30, 2026
- Description
- Schedule 13G beneficial ownership